# A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck Cancer

> **NCT07662720** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Glycyx Therapeutics** · enrollment: 18 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)

## Interventions

- **DRUG:** axelopran
- **DRUG:** Pembolizumab

## Key facts

- **NCT ID:** NCT07662720
- **Lead sponsor:** Glycyx Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-15
- **Primary completion:** 2027-08-31
- **Final completion:** 2028-08-31
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-07-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07662720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07662720, "A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck Cancer". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07662720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*